（文章来源：证券日报） 证券日报网讯 8月8日晚间，中国医药发布公告称，公司将于2025年8月27日召开2025年第六次临时股东 大会。本次股东大会将审议《关于修订的议案》《关于修订的议案》等多项议案。 ...

Meeting Overview - The 30th meeting of the 9th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on August 8, 2025, combining in-person and communication methods, chaired by Chairman and General Manager Yang Guang [1] - All 7 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and Articles of Association, making the resolutions valid [1] Resolutions Passed - The meeting approved the proposal to amend the Articles of Association, with a unanimous vote of 7 in favor [2] - The proposal to amend the Rules of Procedure for Shareholders' Meetings was also approved, with a unanimous vote of 7 in favor [2] - The proposal to amend the Rules of Procedure for Board Meetings received unanimous approval, with 7 votes in favor [2] - The proposal to amend the Independent Director System was approved unanimously, with 7 votes in favor [2] - The proposal to amend the External Guarantee Management System was approved unanimously, with 7 votes in favor [2] - The board agreed to nominate Ms. Sun Zhuo as a candidate for director, pending approval at the shareholders' meeting, with a unanimous vote of 7 in favor [3] Other Decisions - The board decided to waive the priority right to acquire a 5% limited partnership interest in the Life and Health Industry Fund, which corresponds to a subscribed capital of 100 million yuan and a paid-in capital of 40 million yuan, with the transfer price set at a minimum of 39.5805 million yuan [4][5] - The board approved the proposal to convene the sixth temporary shareholders' meeting of 2025, with a unanimous vote of 7 in favor [6]

(二)本次会议通知于2025年8月1日以邮件、短信、电话或传真的方式向全体监事 发出。 证券代码：600056 证券简称：中国医药 公告编号：临2025-066号 中国医药健康产业股份有限公司 第九届监事会第 14 次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届监事会第14次会 议（以下简称"本次会议"）于2025年8月8日以现场结合通讯方式召开，会议由监事 会主席强勇先生主持。 具体情况请详见公司在上海证券交易所网站（www.sse.com.cn）发布的临 表决结果：同意 4 票；反对 0 票；弃权 0 票。 本议案尚需提交股东大会审议通过。 特此公告。 中国医药健康产业股份有限公司监事会 (三)本次会议应出席会议监事4名，实际参加会议监事4名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为有 效决议。 二、会议审议情况 本次会议审议并通过了《关于取消监事会并废止 <监事会议事规则> 的议案》。 根据《公 ...

Group 1 - The legal opinion letter confirms that the procedures for convening and holding the shareholder meeting comply with the Company Law, Shareholder Meeting Rules, and the company's articles of association [2][3][6] - The shareholder meeting is scheduled for August 8, 2025, with both on-site and online voting options available [2][3] - The total number of shares represented at the meeting was 648,953,202 shares from on-site participants and 13,190,318 shares from online voters, accounting for 44.2644% of the total voting shares [4][5] Group 2 - The voting results showed that 658,792,760 shares were in favor of the proposals, representing 99.4939% of the valid votes cast [5][6] - The small and medium-sized investors' votes indicated that 30,490,912 shares were in favor, which is 90.0987% of the valid votes from this group [5][6] - The legal opinion concludes that the voting methods and results are valid and comply with relevant laws and regulations [6]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-065 号 中国医药健康产业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年8月27日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、召开会议的基本情况 (一)股东大会类型和届次 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 8 月 27 日14 点 30 分 召开地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 (五)网络投票的系统、起止日期和投票时间。 网络投票起止时间：自2025 年 8 月 27 日 至2025 年 8 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-061 号 中国医药健康产业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 一、 会议召开和出席情况 和平先生列席本次会议。 二、 议案审议情况 (一) 非累积投票议案 审议结果：通过 表决情况： (一) 股东大会召开的时间：2025 年 8 月 8 日 (二) 股东大会召开的地点：北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，由董事长、总经理杨光先生主持。本次会议的 召集、召开、表决方式符合有关法律、行政法规和《公司章程》的有关规定。 (五) 公司董事、监事和董事会秘书的出席情况 中国医药健康产业股份有限公司董事会 | | 股东类型 | 同意 | | | 反对 | 弃权 | | | | | --- | --- | - ...

Overall Revision Summary - The company has revised its Articles of Association to enhance governance structure and compliance with the updated Company Law and relevant regulations [1][2] - The company will abolish the supervisory board and its rules, transferring its responsibilities to the Audit and Risk Control Committee of the board [2][3] Key Amendments to Articles of Association - The term "Shareholders' Meeting" has been standardized to "Shareholders' Assembly," and new sections regarding controlling shareholders, independent directors, and board committees have been added [2][3] - The company will no longer have a supervisory board, and the current supervisors will cease their roles, with the Audit and Risk Control Committee assuming the supervisory functions [2][3] - The revised Articles emphasize the importance of legal compliance and governance, aligning with the principles of the Communist Party of China [4][5] Governance and Management Structure - The Articles outline the responsibilities of the board of directors as the legal representatives of the company, including the appointment of a new legal representative within 30 days if the current one resigns [3][4] - The company aims to strengthen its legal governance and compliance management, ensuring the protection of the rights of shareholders and creditors [4][5] Company Mission and Values - The company’s mission is to enhance the quality of life through technological advancement and integrity, focusing on high-quality development and maximizing shareholder value [6][7] - The company is committed to becoming a trusted global provider of pharmaceutical and medical device services, contributing to national health initiatives and the Belt and Road Initiative [6][7] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in decision-making processes, including the right to request meetings and propose agenda items [12][13] - The company emphasizes the obligation of shareholders to comply with laws and regulations, ensuring responsible exercise of their rights [18][19] Financial and Operational Governance - The company will implement strict regulations regarding external guarantees, requiring shareholder approval for guarantees exceeding certain thresholds [25][26] - The Articles stipulate that the company must maintain transparency in its financial dealings and adhere to regulatory requirements for information disclosure [26][27]

曾任通用技术集团国际控股有限公司人力资源部（党委组织部）总经理、中 国通用技术（集团）控股有限责任公司党群工作部（党组宣传部、党组统战部、 企业文化部）副部长。 现任中国通用技术（集团）控股有限责任公司人力资源部（党组组织部）副 部长、老干部服务中心主任。 特此公告。 证券代码：600056 证券简称：中国医药 公告编号：临2025-064号 中国医药健康产业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经董事会提名委员会审查合格，并经中国医药健康产业股份有限公司（以下 简称"公司"）第九届董事会第30次会议审议通过，董事会提名孙卓女士为公司 第九届董事会董事候选人，任期自股东大会通过之日至本届董事会届满。该事项 尚需提交公司股东大会审议通过。 董事候选人简历如下： 孙卓女士，44岁，研究生，政工师。 中国医药健康产业股份有限公司董事会 ...

中国医药健康产业股份有限公司章程 （2025 年 8 月修订） 第一章总则 第一条为维护中国医药健康产业股份有限公司（以下简称 "公司"或"本公司"）、股东、职工和债权人的合法权益，规 范公司的组织和行为，坚持依法治企、合规经营，加强法治建设， 提高依法治企管理水平，根据《中华人民共和国公司法》（以下 简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司章程指引》《上市公司股东会规则》《上 海证券交易所股票上市规则》和其他有关规定，制定本章程。 第二条公司系依照《公司法》和其他有关规定成立的股份有 限公司。 公司经国家经济体制改革委员会《关于同意设立中技贸易 股份有限公司的批复》批准，以募集方式设立，公司股本总额 为 12,000 万股，每股金额为 1 元人民币；在北京市市场监督管 理局注册登记，取得营业执照，统一社会信用代码 第三条公司于 1997 年 4 月 18 日经中国证券监督管理委员会 批准，首次向社会公众发行人民币普通股 3000 万股，于 1997 年 公司于 2000 年 9 月 30 日经中国证券监督管理委员会核准， 增资扩股 1,035 万股，其中可流通部分 ...

Core Viewpoint - China National Pharmaceutical Group announced the convening of its 30th board meeting on August 8, 2025, to review various proposals, including amendments to existing documents [2] Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Group is as follows: - Pharmaceutical commerce accounts for 77.31% - Pharmaceutical trade accounts for 14.35% - Chemical preparations account for 4.47% - Raw materials account for 2.78% - Traditional Chinese medicine accounts for 1.47% [2]